Notice of Allowability	Application No.	Applicant(s)
	09/654,276	COHEN ET AL.
	Examiner	Art Unit
	Anne Marie S. Wehbe	1633
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed on 9/25/06.		
2. The allowed claim(s) is/are <u>1-3,5,6,9,10,18 and 22</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☒ Information Disclosure Statements (PTO/SB/08), Paper No. (Mail Date)	5. ☐ Notice of Informal Pa 6. ☐ Interview Summary Paper No./Mail Date 7. ☑ Examiner's Amendm	(PTO-413), e
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8.	nt of Reasons for Allowance

EXAMINER'S AMENDMENT

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/25/06 has been entered. Claims 4, 7-8, 11-17, 19-21, and 23-24 are canceled. Claims 1-3, 5-6, 9-10, 18, and 22 are pending in the instant application.

The information disclosure statement (IDS) submitted on 9/25/06 was filed after the mailing date of the final rejection on 4/25/06. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. An initialed copy of the IDS is included with this action.

Applicant's cancellation of previously pending claims 16-17, 19-21, and 23-24 has overcome all rejections of those claims.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Application/Control Number: 09/654,276

Art Unit: 1633

Authorization for this examiner's amendment was given in a telephone interview with Gregory Sebald on 10/27/06.

Page 3

- 1. In claim 1, step d), the phrase "the myocardial tissue" has been replaced by the phrase -- myocardial tissue --.
- 2. In the specification, page 6, line 17, the phrase -- (A+B)-- has been inserted after "Fig. 1".
- 3. In the specification, page 7, line 5, the phrase -- (A-C) -- has been inserted after "Fig. 7".
- 4. In the specification, page 7, line 27, the phrase -- (A+B)-- has been inserted after "Fig. 14".

Claims 1-3, 5-6, 9-10, 18, and 22 are considered free of the prior art of record and allowable.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner's supervisor, Dave Nguyen, can be reached at (571) 272-0731. For all official communications, **the new technology center fax number is (571) 273-8300**. Please note that all official communications and responses sent by fax must be directed to the technology

Application/Control Number: 09/654,276

Art Unit: 1633

center fax number. For informal, non-official communications only, the examiner's direct fax

number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval

system (PAIR) on the internet for patent application status and history information, and for

electronic images of applications. For questions or problems related to PAIR, please call the

USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197.

Representatives are available daily from 6am to midnight (EST). When calling please have your

application serial number or patent number available. For all other customer support, please call

the USPTO call center (UCC) at 1-800-786-9199.

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D PRIMARY EXAMINER

Page 4